Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

Francesco GrossiLung Cancer Unit, AOU San Martino IST – Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Correspondence[email protected]

Jaafar BennounaInstitut de Cancérologie de l’Ouest, Nantes, France;

Libor HavelThomayer Hospital, Prague, Czech Republic;

Maximillian HochmairDepartment of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna, Austria;

Teresa AlmodovarServiço de Pneumologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dong-ming Wu, Teng Liu, Shi-hua Deng, Rong Han, Ting Zhang, Jing Li & Ying Xu. (2020) Alpha-1 Antitrypsin Induces Epithelial-to-Mesenchymal Transition, Endothelial-to-Mesenchymal Transition, and Drug Resistance in Lung Cancer Cells. OncoTargets and Therapy 13, pages 3751-3763.
Read now

Articles from other publishers (2)

Francesco Grossi, Piotr Jaśkiewicz, Marion Ferreira, Grzegorz Czyżewicz, Dariusz Kowalski, Libero Ciuffreda, Ramon Garcia-Gomez, Salvatore Caruso, Joaquim Bosch-Barrera, Stéphanie Gautier, Christine Ta Thanh Minh, Sébastien Henriet & Gilberto de CastroJr.Jr.. (2021) Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic Advances in Medical Oncology 13, pages 175883592110229.
Crossref

Takumi TanikawaReina SuzukiTeppei SuzukiTomoki IshikawaHiroko YamashinaShintaro TsujiKatsuhiko Ogasawara. (2019) Where Does Telemedicine Achieve a Cost Reduction Effect? Cost Minimization Analysis of Teleradiology Services in Japan. Telemedicine and e-Health 25:12, pages 1174-1182.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

Citations (3)

Read on this site (1)

Articles from other publishers (2)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date